Roivant

📍 New York, United States👥 260 employees💰 Last funded 2025
Biotechnology🌐 roivant.com
Website LinkedIn
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.
7
Total investors
2
Early stage
1
Mid stage
2
Late stage
—
Founded

Investors

7 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
United States
5
South Korea
1
United Kingdom
1
Investor activity2014–2025 · investors recorded per year
2014220182202012021120251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Roivant?
Roivant has 7 investors on record on gritt.io, including 2 early-stage backers, 1 mid-stage and 2 late-stage investors.
When did Roivant last raise funding?
The most recent investment in Roivant recorded on gritt.io was in 2025.
What industry is Roivant in?
Roivant operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Roivant based?
Roivant is headquartered in New York, United States.